Xenon's Azetukalner Cuts Seizure Frequency by 53% in Phase 3 Trial, Poised for First-in-Class FDA Submission
Phase 3 data presented at AAN 2026 show azetukalner nearly halved seizure frequency in treatment-resistant focal epilepsy, with 38% of long-term patients achieving over a year of seizure freedom.
5 min read3 sources